A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14741 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Shivang Joshi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Community Neuroscience Services, Westborough, Massachusetts, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Health Care Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
To describe treatment patterns and direct healthcare costs over 3 years following initiation of standard of care acute and preventive migraine medications in patients with migraine in the United States.
Background
There are limited data on long‐term (>1 year) migraine treatments patterns and associated outcomes.
Methods
This was a retrospective, observational cohort study using US claims data from the IBM ® MarketScan ® Research Database (January 2010–December 2017). Adults were included if they had a prescription claim for acute migraine treatments (AMT) or preventive migraine treatments (PMT) in the index period (January 2011–December 2014). The AMT cohort was categorized as persistent, cycled, or added‐on subgroups; the PMT cohort was categorized PMT‐persistent, switched without gaps, or cycled with gaps. Migraine‐specific annual direct costs (2017 US$) across AMT and PMT cohort subgroups were summarized at baseline through 3 years from index (follow‐up).
Results
During the index period, 20,778 and 42,259 patients initiated an AMT and a PMT, respectively. At the 3‐year follow‐up, migraine‐specific direct costs were lower in the persistent subgroup relative to the non‐persistent subgroups in both AMT (mean [SD]: $789 [$1741] vs. $2847 [$8149] in the added‐on subgroup and $862 [$5426] for the cycled subgroup) and PMT cohorts (mean [SD]: $1817 [$5892] in the persistent subgroup vs. $4257 [$11,392] in the switched without gaps subgroup and $3269 [$18,540] in the cycled with gaps subgroup). Acute medication overuse was lower in the persistent subgroup (1025/6504 [27.2%]) vs. non‐persistent subgroups (11,236/58,863 [32.2%] in cycled with gaps subgroup and 1431/6504 [39.4%] in the switched without gaps subgroup). Most patients used multiple acute (19,717/20,778 [94.9%]) or preventive (38,494/42,259 [91.1%]) pharmacological therapies over 3 years following treatment initiation. Gaps in preventive therapy were common; an average gap ranged from 85 to 211 days (~3–7 months).
Conclusion
Migraine‐specific annual healthcare costs and acute migraine medication overuse remained lowest among patients with persistent AMT and PMT versus non‐persistent treatment. Study findings are limited to the US population. Future studies should compare costs and associated outcomes between newer preventive migraine medications in patients with migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Community Neuroscience Services, Westborough, Massachusetts, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Syneos Health, Morrisville, North Carolina, USA.
- TechData Service Company, LLC, King of Prussia, Pennsylvania, USA.
Förderung
- Eli Lilly and Company
Zitieren
APA
Joshi, S., Spargo, A., Hoyt, M., Panni, T., Viktrup, L., Kim, G., Hasan, A., Liu, Y. Y., & Zakharyan, A. (2024). A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14741
Vancouver
Joshi S, Spargo A, Hoyt M, Panni T, Viktrup L, Kim G, et al. A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14741
BibTeX
@article{Joshi2024,
author = {Joshi, Shivang and Spargo, Andrew and Hoyt, Margaret and Panni, Tommaso and Viktrup, Lars and Kim, Gilwan and Hasan, Anthony and Liu, Yan Yun and Zakharyan, Armen},
title = {A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14741}
}
EUVIMED